Kết quả hóa trị bổ trợ phác đồ Xelox ở bệnh nhân ung thư dạ dày tại Bệnh viện Trung ương Thái Nguyên

Evaluating the results of adjuvant chemotherapy with XELOX regimen in gastric cancer patients at Thai Nguyen General hospital period 2021 – 2024. Methods: Cross-sectional descriptive study on 27 patients diagnosed with stage II - III gastric cancer receiving adjuvant chemotherapy with XELOX regimen at the Oncology Center - Thai Nguyen General Hospital from 03/2021 to 03/2024. Results: The male/female ratio is 2/1, the average age of disease is 62.63 ± 6.06 months. 51.85% of patients had less than 16 lymph nodes removed. Poorly differentiated adenocarcinoma accounts for the most with 55.56%. The main tumor stage is T4a, accounting for 40.74%, N1 lymph node metastasis accounts for the highest rate at 40.74%, and the most common disease stage is stage IIA, accounting for 37.04%. The overall survival and disease-free survival rates at 1 year were 88.89% and 70.07%. The overall survival and disease-free survival rates of 13 patients followed for 24 months were 92.31% and 69.23%, respectively. Conclusion: Gastric cancer is often detected when the tumor is large and has metastasized to lymph nodes. In our study, Adjuvant chemotherapy with XELOX regimen helped achieve overall survival and disease-free survival.